摘要
目的探讨心力衰竭并发室性心律失常患者采用厄贝沙坦联合胺碘酮治疗的临床效果。方法将我院2013年3月-2014年3月接收的60例心力衰竭并发室性心律失常患者作为研究对象,按照数字随机法将其分为观察组与对照组各30例,均给予其利尿、强心以及扩血管等治疗,给予对照组胺碘酮治疗,观察组在对照组的基础上施加厄贝沙坦治疗,对比其心功能治疗总有效率与VA治疗总有效率以及生活质量改善情况。结果观察组左室短轴缩短率、左室射血分数、主动脉瓣峰值流速(AVm/s)高于对照组。两组间主动脉内径、主肺动脉内径、左房径、左室径等无显著性差异(P>0.05),观察组心功能分级Ⅰ、Ⅱ级多于对照组,6分钟步行距离、明尼苏达生活质量评分均优于对照组,组间比较差异显著,具有统计学意义(P<0.05);观察组24小时平均心率(90.2±2.3)BPM、24小时单发室性早搏次数(680.2±16.5)个、成对室性早搏次数(17.2±4.3)对、室速(6.3±2.1)阵均少于对照组(98.2±6.5)BPM、(882.3±23.5)个、(22.3±2.8)对、室速(9.8±2.5)阵,差异具有统计学意义(P均<0.05)。结论心力衰竭并发室性心律失常患者采用胺碘酮联合厄贝沙坦治疗后,可有效改善患者的心功能,缓解室性心率失常症状,改善患者生活质量,值得临床推广应用。
Objective To investigate the clinical efficacy of irbesartan combined with amiodarone in patients with heart failure complicated by ventricular arrhythmia. Methods A total of 60 patients with heart failure complicated by ventricular arrhythmia treated in our hospital between March 2013 and March 2014 were selected, and randomly divided into observation group and control group, with 30 patients in each group. All the patients were given treatments for diuresis, tonifying the heart, and dilating blood vessels; the control group was given amiodarone, while the observation group was given irbesartan additionally. The overall response rates in terms of heart function and ventricular arrhythmias and the improvement in quality of life were compared between the two groups. Results The observation group had higher left ventricular minor axis decurtation rate, left ventricular ejection fraction, and peak flow velocity of the aortic valve （AVm/s） than the control group. The two groups had insignificant differences in aortic dimension, aortopulmonary dimension, left atrial dimension, and left ventricular dimension （P〉O.05）; the observation group had significantly greater numbers of individuals with cardiac functional grades I and II and a significantly better score of Minnesota Living with Heart Failure Questionnaire （MLHFQ） compared with the control group （P〈O.05）; 24-h mean heart rate, times of single premature ventricular contraction, times of paired premature ventricular contraction, and times of ventricular tachycardia in 24 h of the observation group were 90.2±2.3 bpm, 680.2±16.5, 17.2±4.3 pairs, and 6.3±2.1, respectively, significantly less than those of the control group （98.2±6.5 bpm, 882.3±23.5, 22.3±2.8 pairs, and 9.8±2.5, respectively） （all P〈O.05）. Conclusion Use of amiodarone combined with irbesartan in patients with heart failure complicated by ventricular arrhythmia can effectively improve the heart function, relieve the symptoms of ventricular arrhythmia, and improve the quality of life, and consequently is worthy of clinical application.
出处
《心血管病防治知识（学术版）》
2015年第7期71-73,共3页
Prevention and Treatment of Cardiovascular Disease
